|
CANCERS BRONCHIQUES A PETITES CELLULES
TRAITEMENTS BIOLOGIQUES: THALIDOMIDE |
|
|
Référence |
chimiothérapie |
thalidomide |
modalité |
stade |
nb pts |
SM CT |
SM
CT + Thal |
p |
|
Pujol, 2007
(1) |
VP16-CDDP-CPA-épirubicine |
400 mg/j chez répondeurs |
consolidation |
ME |
92 |
|
|
0,16 |
|
Lee, 2009
(2)
I |
Carbo-VP16 |
100 – 200 mg/ x 2 ans |
combiné |
tous |
724 |
|
|
NS |
Références
(1) Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007 Sep 1;25(25):3945-51.
(2) Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009 Aug 5;101(15):1049-57.